KR101621036B1 - 종양 세포를 동정하기 위한 마커, 그의 방법 및 키트 - Google Patents

종양 세포를 동정하기 위한 마커, 그의 방법 및 키트 Download PDF

Info

Publication number
KR101621036B1
KR101621036B1 KR1020137028327A KR20137028327A KR101621036B1 KR 101621036 B1 KR101621036 B1 KR 101621036B1 KR 1020137028327 A KR1020137028327 A KR 1020137028327A KR 20137028327 A KR20137028327 A KR 20137028327A KR 101621036 B1 KR101621036 B1 KR 101621036B1
Authority
KR
South Korea
Prior art keywords
marker
cells
prognosis
biological
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137028327A
Other languages
English (en)
Korean (ko)
Other versions
KR20140015500A (ko
Inventor
만지리 바크레
Original Assignee
온코스템 다이아그노틱스 (모리셔스) 프라이빗 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코스템 다이아그노틱스 (모리셔스) 프라이빗 리미티드 filed Critical 온코스템 다이아그노틱스 (모리셔스) 프라이빗 리미티드
Publication of KR20140015500A publication Critical patent/KR20140015500A/ko
Application granted granted Critical
Publication of KR101621036B1 publication Critical patent/KR101621036B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
KR1020137028327A 2011-03-27 2012-03-26 종양 세포를 동정하기 위한 마커, 그의 방법 및 키트 Active KR101621036B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2835/CHE/2010 2011-03-27
IN2835CH2010 2011-03-27
PCT/IB2012/051427 WO2012131564A1 (en) 2011-03-27 2012-03-26 Markers for identifying tumor cells, methods and kit thereof

Publications (2)

Publication Number Publication Date
KR20140015500A KR20140015500A (ko) 2014-02-06
KR101621036B1 true KR101621036B1 (ko) 2016-05-13

Family

ID=46877646

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137028327A Active KR101621036B1 (ko) 2011-03-27 2012-03-26 종양 세포를 동정하기 위한 마커, 그의 방법 및 키트

Country Status (8)

Country Link
US (2) US8772455B2 (enExample)
EP (1) EP2691776A4 (enExample)
JP (1) JP2014515821A (enExample)
KR (1) KR101621036B1 (enExample)
CN (1) CN103562723B (enExample)
AU (1) AU2012235767B2 (enExample)
SG (1) SG193630A1 (enExample)
WO (1) WO2012131564A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209070A (zh) 2013-03-15 2015-12-30 瓦里安医疗系统公司 用于放射疗法的生物标志物
ES2728305T3 (es) * 2013-04-29 2019-10-23 Ogd2 Pharma Uso como diana del gangliosido GD2 O-acetilado como una nueva estrategia terapéutica y de diagnóstico para cáncer de células madre cancerosas
US10839509B2 (en) 2015-07-10 2020-11-17 3Scan Inc. Spatial multiplexing of histological stains
FR3044680B1 (fr) * 2015-12-02 2017-12-22 Univ Limoges Methode de detection de cellules souches cancereuses
ES2882875T3 (es) * 2016-05-24 2021-12-03 Oncostem Pte Ltd Método de pronóstico y predicción de la recurrencia del cáncer de mama, marcadores empleados en el mismo y kit del mismo
CN106053172B (zh) * 2016-06-03 2018-10-30 浙江世纪康大医疗科技股份有限公司 一种edta抗原修复液
US10166406B2 (en) 2017-02-24 2019-01-01 Varian Medical Systems International Ag Radiation treatment planning and delivery using collision free regions
CN115429881A (zh) * 2022-09-02 2022-12-06 中国医学科学院基础医学研究所 铁螯合剂治疗β-连环蛋白活化突变的肿瘤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042236A2 (en) 2006-09-29 2008-04-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558366A1 (en) * 2004-02-23 2005-09-01 Erasmus Universiteit Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
WO2006016110A1 (en) * 2004-08-10 2006-02-16 University College Cardiff Consultants Limited Methods and kit for the prognosis of breast cancer
WO2007075672A2 (en) * 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
CN101583624B (zh) * 2006-09-29 2012-11-21 昂考梅德药品有限公司 用于诊断和治疗癌症的组合物及其用途
US7968169B2 (en) * 2007-08-07 2011-06-28 The Boeing Company Compound contoured composite beams and fabrication methods
CA2723648A1 (en) * 2008-04-10 2009-10-15 Piyush Gupta Methods for identification and use of agents targeting cancer stem cells
JPWO2011007853A1 (ja) * 2009-07-14 2012-12-27 リンク・ジェノミクス株式会社 癌特異的アイソフォームに対するモノクローナル抗体
US20130059903A1 (en) * 2010-03-12 2013-03-07 The Johns Hopkins University Compositions and Methods for Characterizing Breast Cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042236A2 (en) 2006-09-29 2008-04-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Breast Cancer Research, 2008,10권,R53.
Chinese Medical Journal, 2009,122권,22호,2763-69면.

Also Published As

Publication number Publication date
JP2014515821A (ja) 2014-07-03
WO2012131564A1 (en) 2012-10-04
CN103562723A (zh) 2014-02-05
US8772455B2 (en) 2014-07-08
CN103562723B (zh) 2017-04-26
SG193630A1 (en) 2013-10-30
EP2691776A4 (en) 2015-04-15
KR20140015500A (ko) 2014-02-06
EP2691776A1 (en) 2014-02-05
AU2012235767B2 (en) 2016-02-04
AU2012235767A1 (en) 2013-11-07
US20120244556A1 (en) 2012-09-27
US20140295459A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
KR101621036B1 (ko) 종양 세포를 동정하기 위한 마커, 그의 방법 및 키트
Chen et al. The function of LncRNAs and their role in the prediction, diagnosis, and prognosis of lung cancer
Buckup et al. Plectin is a regulator of prostate cancer growth and metastasis
Balic et al. Circulating tumor cells: from bench to bedside
Said et al. Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders
Miller et al. PD‐L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer
CN105209636A (zh) 用于癌症预后的组合物和方法
Ermiah et al. Prognostic value of proliferation markers: immunohistochemical ki-67 expression and cytometric s-phase fraction of women with breast cancer in libya
JP2012177706A (ja) 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験
Otterstrom et al. CD74: a new prognostic factor for patients with malignant pleural mesothelioma
US10451614B2 (en) Methods of assessing protein interactions between cells
Ge et al. Integrin alpha 7 correlates with poor clinical outcomes, and it regulates cell proliferation, apoptosis and stemness via PTK2-PI3K-Akt signaling pathway in hepatocellular carcinoma
WO2019010429A1 (en) METHODS OF DIAGNOSING PANCREATIC CANCER
Lee et al. Immunohistochemical markers for hepatocellular carcinoma prognosis after liver resection and liver transplantation
van der Toom et al. Analogous detection of circulating tumor cells using the AccuCyte®—CyteFinder® system and ISET system in patients with locally advanced and metastatic prostate cancer
CN108572255A (zh) 检测pd-l1+循环肿瘤细胞的试剂在筛选癌症风险个体以及在癌症患者预后中的应用
Malinowsky et al. Targeted therapies in cancer-challenges and chances offered by newly developed techniques for protein analysis in clinical tissues
JP2012501440A (ja) 内分泌処置予測因子としてのａｎｌｎタンパク質
Eom et al. Prognostic significance of CD44v6, CD133, CD166, and ALDH1 expression in small intestinal adenocarcinoma
EP2710379A1 (en) Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
Kao et al. Molecular biomarkers in malignant mesothelioma: state of the art
EP3391053B1 (en) Methods of detecting a relapse of a lung adenocarcinoma based on marker human epididymis protein 4 (he 4) and related uses
JPWO2016031816A1 (ja) 抗がん剤の感受性の判定マーカー
Du et al. The clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma
Marino et al. Immunohistochemistry of thymic epithelial tumors as a tool in translational research

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131025

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131028

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150305

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20150922

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160324

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160509

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160510

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190510

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190510

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210309

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20220329

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240507

Start annual number: 9

End annual number: 9